Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease - Wikidata - awgldk - TriplyDB

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

http://www.wikidata.org/entity/Q24245911

about

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications Review: management of Parkinson's disease.Pharmacotherapy in Parkinson's disease: case studies.Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.Treatment of Parkinson's disease in the advanced stage.Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease.

P2860

Q24234273-FAC75176-7596-444C-B6DF-9B424BA23725 Q34332812-F09C3850-2AB9-447C-BBAA-DC156095A67F Q34409459-FB3B9003-4A11-45E7-9576-D76FA0E1CEB0 Q34550037-B14A7C5F-C80E-4DE2-803E-B2079A704965 Q36725292-914F5330-2778-405E-98DC-55639B2B0128 Q37164701-A386325C-0E3B-47B2-8075-B77495FDCD2E

P2860

Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

http://www.wikidata.org/entity/Q24245911

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@ast

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en-gb

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@nl

type

label

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@ast

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en-gb

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@nl

prefLabel

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@ast

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en-gb

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@nl

P1433

Q24245911-B7C3F189-40CE-4364-90DE-01943A91CB0E

P1476

Q24245911-01BBBAFA-62D2-4C77-B2BA-2E9916B1B18A

P2093

Q24245911-AE37E8B3-CDC5-4CD6-B9B7-C7D093B9EBB3

Q24245911-FCCDE7B8-F5D6-4F9F-9896-EA86D826AA96

P2860

Q24245911-1909301E-8E4F-4942-B8A8-1220370D9A64

Q24245911-1F393FC0-CE84-4A42-89CA-9A392F517F49

Q24245911-27CA3222-60A0-4814-8D0D-9ECD17CAEE84

Q24245911-33121D3D-E01A-408D-8209-4B14FCCB8E76

Q24245911-368D384E-3237-4ACF-ACB5-24478CC9AF10

Q24245911-38E837EA-A2F2-4147-9D0B-7E8D2B99D9DF

Q24245911-42D38875-D4DC-4467-887D-BF65EAA6AAAC

Q24245911-44F5D042-D774-473E-81A7-549969B54617

Q24245911-475C4772-876B-47EF-B2C8-94AB72DBDCF4

Q24245911-54171F93-8E14-41DF-8175-C0242D1B1A15

P31

Q24245911-2A725A1C-0E59-4ABF-B444-5018C857627C

P356

Q24245911-9D66B6EE-2E53-494E-8367-DCED47D0CA10

P50

Q24245911-4F29F76B-5559-4A21-9E77-2A082832EBD6

P577

Q24245911-CA19151D-9A2A-4F73-B438-8789D656D36C

P698

Q24245911-1C5818DA-60C9-4786-B1A7-0BEBD8382B13

P921

Q24245911-1F709DC8-56BF-45D8-A905-B3159CCE55E1

Q24245911-96AEE254-8504-4CB1-84BA-6D7695C3A0F5

P356

14651858.CD004554.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Catechol-O-methyltransferase i ...... cations in Parkinson's disease

@en

P2093

Carl E Clarke

http://www.w3.org/2001/XMLSchema#string

Sybille Spieker

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

The rise and fall of tolcapone.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

P31

scholarly article

P356

10.1002/14651858.CD004554.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

Katherine Deane

P577

2004-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15495119

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease